JO3333B1 - Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes - Google Patents

Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes

Info

Publication number
JO3333B1
JO3333B1 JOP/2014/0244A JOP20140244A JO3333B1 JO 3333 B1 JO3333 B1 JO 3333B1 JO P20140244 A JOP20140244 A JO P20140244A JO 3333 B1 JO3333 B1 JO 3333B1
Authority
JO
Jordan
Prior art keywords
dimethylpropan
aminium
carboxy
ethyl
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0244A
Other languages
Arabic (ar)
Inventor
Liepins Edgars
Misane Ilga
Makarova Elina
Kalvins Ivars
Dambrova Maija
Cirule Helena
Original Assignee
Grindeks Jsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks Jsc filed Critical Grindeks Jsc
Application granted granted Critical
Publication of JO3333B1 publication Critical patent/JO3333B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine

Abstract

Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts to decrease blood plasma levels of insulin and glucose.
JOP/2014/0244A 2013-09-26 2014-08-05 Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes JO3333B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13186201 2013-09-26

Publications (1)

Publication Number Publication Date
JO3333B1 true JO3333B1 (en) 2019-03-13

Family

ID=49231372

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0244A JO3333B1 (en) 2013-09-26 2014-08-05 Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes

Country Status (9)

Country Link
CN (1) CN105530929B (en)
AR (1) AR099638A1 (en)
BR (1) BR112016004211B1 (en)
CA (1) CA2924682C (en)
JO (1) JO3333B1 (en)
MX (1) MX368505B (en)
TN (1) TN2016000064A1 (en)
WO (1) WO2015044828A1 (en)
ZA (1) ZA201600894B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2067474A1 (en) * 2007-12-05 2009-06-10 Grindeks, a joint stock company Medical use of 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate
LV14345B (en) * 2009-10-22 2011-07-20 Grindeks, A/S 4-[ethyl(dimethyl)ammonio]butanoate and their use in the treatment of cardiovascular diseases
JP5997762B2 (en) 2011-04-27 2016-09-28 グリンデクス, ア ジョイント ストック カンパニーGRINDEKS, a joint stock company Use of 3-carboxy-N-ethyl-N, N-dimethylpropane-1-aminium salt in the treatment of cardiovascular disease

Also Published As

Publication number Publication date
MX2016003347A (en) 2016-06-24
CN105530929A (en) 2016-04-27
TN2016000064A1 (en) 2017-07-05
CA2924682A1 (en) 2015-04-02
BR112016004211A2 (en) 2017-08-01
BR112016004211B1 (en) 2022-09-06
CA2924682C (en) 2018-02-27
WO2015044828A1 (en) 2015-04-02
ZA201600894B (en) 2017-05-31
CN105530929B (en) 2018-03-02
AR099638A1 (en) 2016-08-10
MX368505B (en) 2019-10-04

Similar Documents

Publication Publication Date Title
PH12015500115B1 (en) Glucagon analogues
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
GB201314512D0 (en) Dual Haemodialysis and Haemodiafiltration blood treatment device
SA517381678B1 (en) Dihydropyrimidin-2-One Compounds and Medical Use Thereof
HK1223529A1 (en) Low glucose treatment for people with diabetes
MX2016011881A (en) Dry-powder peptide medicament.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
PH12016500950A1 (en) Infant nutrition for improvement in insulin sensitivity later in life
TN2016000064A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
MX2013009456A (en) Vinyl -aryl - sulfones for use in peritoneal carcinomatosis.
SI2699545T1 (en) Novel amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
PH12015500306A1 (en) Arry-520 for use in treating cancer in a patient with low aag
PL2852400T3 (en) An insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes
AU2014903587A0 (en) Regulation of a blood glucose level in a patient with diabetes
PH12015500178A1 (en) Injectable supersaturated acetaminophen solution for spinal administration
IN2014DE00818A (en)
UA74052U (en) Method for preventing lateral abdominal wall hernia in patients with functioning colostoma and ventral hernia
GB201304462D0 (en) Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance
UA97741C2 (en) Method for regeneration of skin integuments in patients with deep burns by microautodermotransplants
UA79303U (en) use of taurine as agent for stabilizing the concentration in blood plasma in the treatment of fungal diseases
UA84195U (en) Method for treating influenza in adult patients
UA97054C2 (en) Method for the treatment of patients with dependence owing to application of psychoactive substances